# A Study to Assess Safety and Efficacy of ASP1941 in Combination With Nateglinide in Type 2 Diabetic Patients

Study · id `cardio:ct-nct01316107` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01316107](<https://clinicaltrials.gov/study/NCT01316107>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01316107

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 122 participants.

## Technical summary

Registry record NCT01316107. Allocation not applicable; no masking; primary purpose treatment. Start 2011-01-15 (actual); primary completion 2012-10-19 (actual). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 122 participants (enrolled count; ClinicalTrials.gov record NCT01316107, source copy `cardio:ctgov-nct01316107-2025-05-30`, retrieved 2026-10-26)
- Started: 2011-01-15 (actual) (ClinicalTrials.gov record NCT01316107, source copy `cardio:ctgov-nct01316107-2025-05-30`, retrieved 2026-10-26)
- Primary completion: 2012-10-19 (actual) (ClinicalTrials.gov record NCT01316107, source copy `cardio:ctgov-nct01316107-2025-05-30`, retrieved 2026-10-26)
- Completion: 2012-10-19 (actual) (ClinicalTrials.gov record NCT01316107, source copy `cardio:ctgov-nct01316107-2025-05-30`, retrieved 2026-10-26)
- Countries: Japan (ClinicalTrials.gov record NCT01316107, source copy `cardio:ctgov-nct01316107-2025-05-30`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01316107-2025-05-30`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Study to Assess Safety and Efficacy of ASP1941 in Combination With Nateglinide in Type 2 Diabetic Patients
- Condition: Type 2 Diabetes Mellitus
- Intervention (Drug): ipragliflozin
- Intervention (Drug): nateglinide
- Lead sponsor: Astellas Pharma Inc
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Astellas Pharma Inc (`cardio:org-astellas-pharma-inc`)

## Provenance

Content hash: e3e188049e45de23149dd376782930f15044a7c6d93599122e1711d9620b2de0
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
